

Cidofovir (dihydrate)

Catalog No: tcsc1908



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

149394-66-1

Formula:

$C_8H_{18}N_3O_8P$

Pathway:

Anti-infection

Target:

CMV

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

HPMPC dihydrate;(S)-HPMPC dihydrate

Observed Molecular Weight:

315.22


Product Description

Cidofovir dehydrate is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis, which suppresses virus replication by selective inhibition of viral DNA synthesis.

Target: CMV DNA polymerase

Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir.

Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, by Antonín Holý, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!